The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Open accessPreprint — published as 10.1038/s41586-020-2639-4 · Paper page
Abstract
In March 2020, the WHO declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 With >8.8 million cases and >450,000 deaths reported globally, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 μg, 30 μg, or 100 μg of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8-to 2.8-fold that of a panel of COVID-19 convalescent human sera. These results support further evaluation of this mRNA vaccine candidate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The incidence of grade 3 fever of BNT162b1 varied significantly in the same 30 μg group in adults aged 18–55 years, with none (0%) of 12 in the USA,17 one (8%) of 12 in Germany,18 and four (17%) of 24 in China,16 suggesting varying tolerability in different populations.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Together with recent reports of the preserved neutralization of SARS-CoV-2 with key S mutations found in the B.1.1.7 and the B.1.351lineage 39,40 , and neutralization of pseudovirus bearing the full set of mutations of B.1.1.7 S 41 , our data indicate broad BNT162b2-elicited immune recognition 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To enable the comparison of vaccine-induced S1-and RBD-binding IgG responses to previously reported data on the BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GMTs in subgroups of the donors were as follows: symptomatic infections, 90 (n = 35); asymptomatic infections, 156 (n = 3); hospitalized, 618 (n = 1).”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, several studies17, 18, 19 have reported more frequent and severe solicited systemic adverse events following the second vaccination than we found.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies17, 18, 19 showed that solicited systemic adverse events were more frequent and more severe at higher doses”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with recent reports of mRNA-LNP vaccines against the SARS-CoV-2 virus responsible for the COVID-19 pandemic which had similar rates of reactogenicity and in which reactogenicity noticeably increased after a second dose [17], [18].”
From Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The S glycoprotein mediates host cell attachment and is required for viral entry3; it is the primary vaccine target for many candidate SARS-CoV-2 vaccines.4-7”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those studies showed that solicited systemic adverse events tended to be more frequent and more severe with higher doses and after the second vaccination.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To enable the comparison of vaccine-induced serum neutralizing titres to those previously reported for BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“This descriptive safety profile is similar to that described in a report of two trials of avian influenza mRNA vaccines (influenza A/H10N8 and influenza A/H7N9) that were manufactured by Moderna with the use of an earlier lipid nanoparticle capsule formulation11 and is consistent with an interim report of a phase 1–2 evaluation of a Covid-19 mRNA vaccine encoding the S receptor-binding domain.6”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the use of high doses of mRNA formulated with lipid nanoparticles (LNPs) resulted in some side effects in the candidates mRNA-1273 and BNT162b1.3,4”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [4]
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [152]
In the citing paper
“an mRNA-based vaccine that encodes the full-length SARS-CoV-2 spike (S) gene1”
From SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses (2021) · cites this paper as [1]
In the citing paper
“However, the vaccine developers eventually decide to proceed with BNT162b2 to phase II/III international clinical trials in view of its milder reactogenicity.277,278,378”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“BioNTech and Pfizer collaborated to develop five COVID-19 mRNA vaccine candidates at the beginning of the pandemic, which were based on nucleoside-modified mRNA (BNT162b2, BNT162b1, BNT162b3), non-modified mRNA (BNT162a1) and self-amplifying mRNA (BNT162c2).”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
In the citing paper
“Clinical trial data indicated that both mRNA vaccine candidates induced neutralizing antibodies at a comparable level.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“Till now, all of these candidates have entered clinical trials (Table 5).130,376,377”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
In the citing paper
“8–50-fold higher anti-RBD IgG”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“1.9–4.6-fold higher neutralization titres than convalescent serum27,123”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“In phase I trials of the two candidates, two 30 μg doses delivered 21 days apart induced high antibody and neutralizing titres and a robust CD4+ and CD8+ response with mild to moderate adverse events27,28,123,124.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“with up to 75% showing moderate fever after a 30 μg boost vaccine [82].”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Both local and systemic AE occurred dose-dependently, were mostly mild to moderate and more common after boost vaccination.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“events also peaked at day 2 after dosing and were resolved by day 7.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“despite the lower mRNA-doses used, AEs were reported more frequently with BNT162b1 as compared to mRNA-1273”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Based on the reactogenicity to the 100 μg dose, no boost vaccination was performed at this dosage.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“fever was already reported after the first vaccination for all dose groups (8% for the 10 and 30 μg doses, 50% for the 100 μg dose)”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Results of a phase 1/2 dose-escalation study (mRNA doses of 10–30-100 μg) revealed similar tolerability and safety.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Self-citationCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationCoronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
An Infectious cDNA Clone of SARS-CoV-2
Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,004
Shahrear, S., & Islam, A. B. M. M. K. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10515-4 · Cited by 24
Simón‐Gracia, L., Scodeller, P., Fisher, W. S., Sidorenko, V., Steffes, V. M., Ewert, K. K., Safinya, C. R., & Teesalu, T. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c17961 · Cited by 24
Yao, Y., Zhang, Z., & Yang, Z. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1243835 · Cited by 24
Deciphering the Immunogenicity of Monkeypox Proteins for Designing the Potential mRNA Vaccine
Shah, M., Jaan, S., Shehroz, M., Sarfraz, A., Asad, K., Wara, T. U., Zaman, A., Ullah, R., Ali, E. A., Nishan, U., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c07866 · Cited by 24
Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19
Scarabel, L., Guardascione, M., Bo, M. D., & Toffoli, G. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.035 · Cited by 25
COVID-19 vaccine decisions: considering the choices and opportunities
Hotez, P. J., Nuzhath, T., Callaghan, T., & Colwell, B. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104811 · Cited by 25
Emerging Progress of RNA-Based Antitumor Therapeutics
Fu, J., Dong, H., Wu, J., & Jin, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83732 · Cited by 23
All eyes on a hurdle race for a SARS-CoV-2 vaccine
Gaebler, C., & Nussenzweig, M. C. (2020) · Nature · doi:10.1038/d41586-020-02926-w · Cited by 24
Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines
Lin, D.-Y., Zeng, D., Mehrotra, D. V., Corey, L., & Gilbert, P. B. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1863 · Cited by 22
Resonant Acoustic Mixing Method to Produce Lipid-Based Liquid-Crystal Nanoparticles
Yalçın, D., Rajesh, S., White, J., Howard, S. C., Pigram, P. J., Tran, N. L., & Muir, B. W. (2021) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.1c01300 · Cited by 23
Abo-Helo, N., Muhammad, E., Ghaben-Amara, S., Panasoff, J., & Cohen, S. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.07.021 · Cited by 23
Guzmán-Martínez, O., Guardado, K., de Guevara, E. L., Navarro, S. M., Hernández, C., Zenteno‐Cuevas, R., & Montero, H. (2021) · Vaccines · doi:10.3390/vaccines9090999 · Cited by 26
Racine‐Brzostek, S., Yee, J. K., Sukhu, A. C., Qiu, Y., Rand, S., Barone, P. D., Hao, Y., Yang, H. S., Meng, Q. H., Apple, F. S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151477 · Cited by 25
Vaccines against COVID-19: Priority to mRNA-Based Formulations
Pascolo, S. (2021) · Cells · doi:10.3390/cells10102716 · Cited by 23
COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran
Vaezi, A., & Meysamie, A. (2021) · Vaccines · doi:10.3390/vaccines10010037 · Cited by 22
Graves‘ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases
Triantafyllidis, K. K., Giannos, P., Stathi, D., & Kechagias, K. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.938001 · Cited by 23
Reynolds, L., Dewey, C. E., Asfour, G., & Little, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229716 · Cited by 24
Cao, L., Yu, Y.-F., Li, Z., Zhong, N., Wang, G.-R., Xiao, Y., Liu, B., Wu, Q., Feng, C., & Bu, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02590-6 · Cited by 28
COVID-19: The Effect of Host Genetic Variations on Host–Virus Interactions
Chakravarty, S. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00637 · Cited by 23
Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 24
Coarse-Grained Simulation of mRNA-Loaded Lipid Nanoparticle Self-Assembly
Grzetic, D. J., Hamilton, N. B., & Shelley, J. C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00216 · Cited by 22
Ashraf, O., Virani, A., & Cheema, T. J. (2020) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000346 · Cited by 24
To get or not to get: Examining the intentions of Philippine teachers to vaccinate against COVID-19
Cahapay, M. B. (2021) · Journal of Human Behavior in the Social Environment · doi:10.1080/10911359.2021.1896409 · Cited by 25
Overview of approved and upcoming vaccines for SARS-CoV-2: a living review
Alderson, J., Batchelor, V., O’Hanlon, M., Cifuentes, L., Richter, F. C., & Kopycinski, J. T. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab010 · Cited by 22
Connecting primitive phase separation to biotechnology, synthetic biology, and engineering
Jia, T. Z., Wang, P., Niwa, T., & Mamajanov, I. (2021) · Journal of Biosciences · doi:10.1007/s12038-021-00204-z · Cited by 22
Masuda, A., Lee, J. M., Miyata, T., Mon, H., Sato, K., Oyama, K., Sakurai, Y., Yasuda, J., Takahashi, D., Ueda, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803647 · Cited by 21
Kantarcıoğlu, B., Iqbal, O., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Ligocki, M. A., Jeske, W. P., Adıgüzel, C., Gerotziafas, G., et al. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211056648 · Cited by 25
Efficacy of COVID-19 vaccines by race and ethnicity
Salari, N., Vepa, A., Daneshkhah, A., Darvishi, N., Ghasemi, H., Khunti, K., & Mohammadi, M. (2022) · Public Health · doi:10.1016/j.puhe.2022.04.009 · Cited by 23
Addressing COVID-19 vaccine hesitancy
Kassianos, G. C., Puig‐Barberà, J., Dinse, H., Teufel, M., Türeci, Ö., & Pather, S. (2022) · Drugs in Context · doi:10.7573/dic.2021-12-3 · Cited by 22
Self-citationmRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23
Nakafero, G., Grainge, M. J., Card, T. R., Mallen, C. D., Nguyen‐Van‐Tam, J. S., Williams, H. C., & Abhishek, A. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac484 · Cited by 22
Al-Sheboul, S. A., Brown, B., Shboul, Y., Fricke, I., Imarogbe, C., & Alzoubi, K. H. (2022) · Vaccines · doi:10.3390/vaccines11010051 · Cited by 23
Gui, Y., Li, X., Li, J., Shen, M., Zhang, M., Cao, Y., Xu, H., Li, H., Cheng, J., Pan, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104586 · Cited by 21
Roy, S., Ghani, K., de Campos-Lima, P. O., & Caruso, M. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198305 · Cited by 23
A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2Preprint
Cai, X., Prominski, A., Lin, Y., Ankenbruck, N., Rosenberg, J., Chen, M., Shi, J.-Y., Chang, E., Penaloza-MacMaster, P., Tian, B.-Z., et al. (2020) · bioRxiv · doi:10.1101/2020.11.30.404624 · Cited by 12
Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/z4x7t · Cited by 22
Foster, J., Madsen, P. J., Harvey, K., Griffin, C., Stern, A., Patterson, L., Joshi, N., Dickson, C. R., McManus, O., Beaubien, E., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf115 · Cited by 21
Bates, S. M., Munson, M. J., Trovisco, V., Pereira, S. G. T., Miller, S. R., Sabirsh, A., Betts, C. J., Blenke, E. O., & Gay, N. J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114047 · Cited by 26
The landscape of nanomedical clinical trials
Gultepe, E., Valluru, R., Brown, N. B., & Sridhar, S. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102898 · Cited by 25
COVID-19 et vaccination : une dérégulation globale
Billon-Denis, E., & Tournier, J. (2020) · médecine/sciences · doi:10.1051/medsci/2020203 · Cited by 25
SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development
Mehmood, I., Ijaz, M., Ahmad, S., Ahmed, T., Bari, A., Abro, A., Allemailem, K. S., Almatroudi, A., & Qamar, M. T. U. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041626 · Cited by 22
The importance of genomic analysis in cracking the coronavirus pandemic
Zella, D., Giovanetti, M., Cella, E., Borsetti, A., Ciotti, M., Ceccarelli, G., d’Ettorre, G., Pezzuto, A., Tambone, V., Campanozzi, L. L., et al. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1917998 · Cited by 23
Influenza Virus and SARS-CoV-2 Vaccines
Sandor, A., Sturdivant, M. S., & Ting, J. P. ‐. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001287 · Cited by 23
Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
Coppeta, L., Somma, G., Ferrari, C., Mazza, A., Rizza, S., Aurilio, M. T., Perrone, S., Magrini, A., & Pietroiusti, A. (2021) · Vaccines · doi:10.3390/vaccines9090947 · Cited by 21
Yahata, S., Hirose, M., Ueno, T., Nagumo, H., & Sakai‐Kato, K. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00452 · Cited by 22
Sala, L. L., Gandini, S., Bruno, A., Allevi, R., Gallazzi, M., Senesi, P., Palano, M. T., Meregalli, P., Longhi, E., Sommese, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.798813 · Cited by 23
Curvature effects in charge-regulated lipid bilayers
Khunpetch, P., Majee, A., & Podgornik, R. (2022) · Soft Matter · doi:10.1039/d1sm01665b · Cited by 21
Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV
Bessen, C., Plaza‐Sirvent, C., Simsek, A., Bhat, J., Marheinecke, C. S., Urlaub, D., Bonowitz, P., Buße, S., Schumann, S., Blanco, E. V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049070 · Cited by 23
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu, Z., & Fisher, D. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155728 · Cited by 21
Yao, J., Atasheva, S., Wagner, N. J., Paolo, N. C. D., Stewart, P. L., & Shayakhmetov, D. M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.023 · Cited by 23
Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
Hosseini, S. A., Zahedipour, F., Mirzaei, H., & Oskuee, R. K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107622 · Cited by 26
Therapeutic vaccine for chronic diseases after the COVID-19 Era
Nakagami, H., Hayashi, H., Shimamura, M., Rakugi, H., & Morishita, R. (2021) · Hypertension Research · doi:10.1038/s41440-021-00677-3 · Cited by 22
Guragain, P., Tkachov, M., Båtnes, A. S., Ôlsen, Y., Winge, P., & Bones, A. M. (2021) · Frontiers in Marine Science · doi:10.3389/fmars.2021.701793 · Cited by 23
Fox, A., Norris, C. A., Amanat, F., Zolla‐Pazner, S., & Powell, R. L. R. (2021) · medRxiv · doi:10.1101/2021.03.22.21253831 · Cited by 20
Legere, R. M., Cohen, N. D., Poveda, C., Bray, J. M., Barhoumi, R., Szule, J. A., de la Concha-Bermejillo, A., Bordin, A. I., & Pollet, J. (2021) · Scientific Reports · doi:10.1038/s41598-020-79855-1 · Cited by 20
Kyei-Barffour, I., Akwetey, S. A., Aninagyei, E., Ghartey‐Kwansah, G., & Acheampong, D. O. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112282 · Cited by 21
Animal Models of COVID-19 II. Comparative Immunology
Veenhuis, R. T., & Zeiss, C. J. (2021) · ILAR Journal · doi:10.1093/ilar/ilab010 · Cited by 21
Jeda, A. S., Abbassi, S., Mousavizadeh, A., Esghaie, M., Bokharaei‐Salim, F., Jeddi, F., Shafaati, M., & Abdoli, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108232 · Cited by 22
Nanoscience versus Viruses: The SARS‐CoV‐2 Case
Gościańska, J., Freund, R., & Wuttke, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107826 · Cited by 21
Özakbaş, S., Baba, C., Doğan, Y., Çevik, S., Özçelik, S., & Kaya, E. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103486 · Cited by 20
Association of COVID-19 vaccination with herpes zoster: a systematic review and meta-analysis
Chu, C., Jiesisibieke, Z. L., Yang, Y., Wu, P., Lin, H.-L., & Tung, T. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2036128 · Cited by 21
Inchingolo, A. D., Malcangi, G., Ceci, S., Patano, A., Corriero, A., Vimercati, L., Azzollini, D., Marinelli, G., Coloccia, G., Piras, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158485 · Cited by 22
Long-Term Antibody Response to SARS-CoV-2 in Children
Dunay, G. A., Barroso, M., Woidy, M., Danecka, M. K., Engels, G., Hermann, K., Neumann, F. S., Paul, K., Beime, J., Escherich, G., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01355-w · Cited by 24
Stærke, N. B., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Søgaard, O. S., Tolstrup, M., Iversen, K. K., Tarp, B., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-069065 · Cited by 21
Serafim, M. S. M., Gertrudes, J. C., Costa, D. M. A., Oliveira, P. R., Maltarollo, V. G., & Honório, K. M. (2021) · Bioscience Reports · doi:10.1042/bsr20202616 · Cited by 22
Carvalho, K., Vicente, J. P., Jakovljević, M., & Teixeira, J. P. (2021) · Bioengineering · doi:10.3390/bioengineering8060084 · Cited by 22
Scaglione, A., Opp, S., Hurtado, A. M., Lin, Z., Pampeno, C., Noval, M. G., Thannickal, S. A., Stapleford, K. A., & Meruelo, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719077 · Cited by 20
Cobb, R. R., Nkolola, J. P., Gilchuk, P., Chandrashekar, A., Yu, J., House, R. V., Earnhart, C. G., Dorsey, N. M., Hopkins, S. A., Snow, D. M., et al. (2022) · Med · doi:10.1016/j.medj.2022.01.004 · Cited by 20
Sáez‐Llorens, X., Lanata, C. F., Aranguren, E., Celis, C. R., Cornejo, R., DeAntonio, R., Ecker, L., Garrido, D., Gil, A. I., Gonzales, M., et al. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100189 · Cited by 20
SARS-CoV-2 infected cells present HLA-I peptides from canonical and out-of-frame ORFsPreprint
Weingarten-Gabbay, S., Klaeger, S., Sarkizova, S., Pearlman, L., Chen, D.-Y., Bauer, M., Taylor, H. B., Conway, H. L., Tomkins-Tinch, C., Finkel, Y., et al. (2020) · bioRxiv · doi:10.1101/2020.10.02.324145 · Cited by 21
Mamedov, T., Yuksel, D., Ilgın, M., Gürbüzaslan, İ., Gulec, B., MAMMADOVA, G., Say, D., & Hasanova, G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.29.424779 · Cited by 20
Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape StrategiesPreprint
Lan, S., Neilsen, G., Slack, R. L., Cantara, W. A., Castaner, A. E., Lorson, Z. C., Lulkin, N., Zhang, H., Lee, J., Cilento, M. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.31.522389 · Cited by 22
Low, J. G., de Alwis, R., Chen, S., Kalimuddin, S., Leong, Y. S., Mah, T. K. L., Yuen, N., Tan, H. C., Zhang, S. L., Sim, J. X. Y., et al. (2021) · doi:10.1101/2021.07.01.21259831 · Cited by 19
Chemical circularization of in vitro transcribed RNA for exploring circular mRNA design
Wąsińska-Kałwa, M., Mamot, A., Czubak, K., Frankowska, K., Rajkiewicz, A. A., Śpiewla, T., Warmiński, M., Pilch, Z., Szulc-Gasiorowska, M., Siekan, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61775-1 · Cited by 27
Harnessing Cellular Immunity for Vaccination against Respiratory Viruses
Lukacs, N. W., & Malinczak, C. (2020) · Vaccines · doi:10.3390/vaccines8040783 · Cited by 20
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13818 · Cited by 18
Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives
Su, H.-Y., & Hsu, Y.-C. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i13.2951 · Cited by 19
Assessment of salivary antibody response to BNT162b2 mRNA COVID‐19 vaccination
Lapić, I., Šegulja, D., & Rogić, D. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27096 · Cited by 19
Bernhauerová, V., Lisowski, B., Rezelj, V. V., & Vignuzzi, M. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110895 · Cited by 19
Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2
Saadi, F., Pal, D., & Sarma, J. D. (2021) · Annals of Neurosciences · doi:10.1177/09727531211023755 · Cited by 17
Risma, K. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001077 · Cited by 21
The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients
Alsaffar, W. A., Alwesaibi, A. A., Alhaddad, M. J., Alsenan, Z. K., Alsheef, H. J., AlRamadan, S., Aljassas, H. A., Alsaghirat, M. A., & Alzahrani, H. J. (2022) · Cureus · doi:10.7759/cureus.21485 · Cited by 19
Simões, R. S. D. Q., & Rodrı́guez-Làzaro, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042392 · Cited by 22
The Fundamental Flaws of the CNBSS Trials: A Scientific Review
Seely, J. M., Eby, P. R., & Yaffe, M. J. (2022) · Journal of Breast Imaging · doi:10.1093/jbi/wbab099 · Cited by 19
Dayie, T. K., Olenginski, L. T., & Taiwo, K. M. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00845 · Cited by 21
Chen, J., Li, F., Tian, J., Xie, X., Tang, Q., Chen, Y., & Ge, Y. L. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28307 · Cited by 19
Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines
Neto, A. R. D. S., de Carvalho, A. R. B., da Silva, M. D. F., Neta, M. M. R., Sena, I. V. D. O., Almeida, R. N., Filha, F. S. S. C., Silva, L. L. L. E., da Costa, G. R., Lira, I. M. D. S., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064796 · Cited by 20
Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies
Reinig, S., & Shih, S. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100666 · Cited by 22
Inkjet printing-based high-throughput DNA synthesis
Deng, X. J., Li, H., & Song, Y. (2023) · Giant · doi:10.1016/j.giant.2023.100222 · Cited by 22
van den Ouweland, F., Charpentier, N., Türeci, Ö., Rizzi, R., Mensa, F., Lindemann, C., & Pather, S. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2315659 · Cited by 20
Self-citationPharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines
Hofman, K., Shenoy, G. N., Chak, V., & Balu‐Iyer, S. V. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1904977 · Cited by 20
Pokhrel, S., Kraemer, B. R., Burkholz, S., & Mochly‐Rosen, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-92641-x · Cited by 20
Somogyi, E., Csiszovszki, Z., Molnár, L., Lőrincz, O., Tóth, J., Pattijn, S., Schockaert, J., Mazy, A., Miklós, I., Pántya, K., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.684152 · Cited by 18
Nakhostin-Ansari, A., Zimet, G. D., Khonji, M. S., Aghajani, F., Teymourzadeh, A., Kazerooni, A. R., Pirayandeh, P., Aghajani, R., Safari, S., Khalaj, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10050670 · Cited by 20
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates
Kalnin, K. V., Plitnik, T., Kishko, M., Zhang, J., Zhang, D., Beauvais, A., Anosova, N. G., Tibbitts, T., DiNapoli, J. M., Huang, P.-W. D., et al. (2020) · doi:10.1101/2020.10.14.337535 · Cited by 18
Discovery and development of COVID ‐19 vaccine from laboratory to clinic
Saravanan, V., Chagaleti, B. K., Narayanan, P. L., Anandan, V. B., Manoharan, H., Anjana, G. V., Peraman, R., Namasivayam, S. K. R., Kavisri, M., Arockiaraj, J., et al. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14383 · Cited by 19
Analysis of Promising Approaches to COVID-19 Vaccine Development
Онищенко, Г. Г., Sizikova, T. E., Lebedev, V. N., & Borisevich, S. V. (2020) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2020-20-4-216-227 · Cited by 17
Coronavirus disease 2019 vaccination in transplant recipients
Eberhardt, C. S., Balletto, E., Cornberg, M., & Mikulska, M. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000739 · Cited by 18
Coppeta, L., Balbi, O., Grattagliano, Z., Mina, G. G., Pietroiusti, A., Magrini, A., Bolcato, M., & Aurilio, M. T. (2021) · Vaccines · doi:10.3390/vaccines9060659 · Cited by 18
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?
Echeverría, N., Comas, V., Aldunate, F., Perbolianachis, P., Moreno, P., & Cristina, J. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i10.1234 · Cited by 22
Metadata
- Authors
- Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ӧ., Tompkins, K. R., Walsh, E. E., Frenck, R., Falsey, A. R., Dormitzer, P. R., Gruber, W. C., Şahin, U., & Jansen, K. U.
- Affiliations
- NYU Langone Health (US)
- University of Maryland, Baltimore (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (United States) (US)
- The University of Texas Medical Branch at Galveston (US)
- Rochester General Hospital (US)
- Cincinnati Children's Hospital Medical Center (US)
- BioNTech (Germany) (DE)
- Corresponding author
- Absalon, Judith
- ORCID
- Mulligan, Mark J.
- Lyke, Kirsten E.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Neuzil, Kathleen
- Raabe, Vanessa
- Swanson, Kena A.
- Li, Ping
- Cooper, David
- Fontes-Garfias, Camila
- Shi, Pei-Yong
- Tompkins, Kristin R.
- Walsh, Edward E.
- Frenck, Robert
- Falsey, Ann R.
- Dormitzer, Philip R.
- Gruber, William C.
- Şahin, Uğur
- Jansen, Kathrin U.
- Venue
- Nature
- Publisher
- openRxiv
- Published
- 2020-07-01
- Volume
- 586
- Issue
- 7830
- Pages
- 589-593
- ISSN
- 0028-0836 (ISSN-L)
- OpenAlex
- W3048620154
- Cited by
- 1,569
- References
- 24
- Citations by year
- 2026: 47 · 2025: 92 · 2024: 111 · 2023: 183 · 2022: 355 · 2021: 623 · 2020: 152
- FWCI
- 43.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Pfizer
- Cincinnati Children's Hospital Medical Center
- University of Rochester
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health (UL1TR001445)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, dose escalation, vaccine safety, vaccine immunogenicity, neutralizing antibodies, reactogenicity, healthy adults
- MeSH terms
- COVID-19, COVID-19 Vaccines, COVID-19 Serotherapy, Adult, Antibodies, Viral, Female, Humans, Immunoglobulin G, Immunization, Passive, Male, Middle Aged, Pneumonia, Viral, Time Factors, Viral Vaccines, Coronavirus Infections, Young Adult, Antibodies, Neutralizing, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
